Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Adult subjects aged 30 to 75 years at the time of screening/baseline.
Fitzpatrick skin types I-VI.
Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
Willing and able to provide written informed consent form and photography release for research, publication, and/or commercial use.
Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
Use of dermal fillers of any kind during the study period.
Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
Goldman, Butterwick, Fitzpatrick and Groff
Lead sponsor
Obagi
Collaborator